FIGURE 1.

Our protocol of hormone replacement therapy. A steady dose of estrogen agents was administered continuously during the period of withdrawal bleeding. Blood levels of serum FSH, LH, E₂, and P₄ were analyzed at each visit, and when the E₂ level was 80‐100 pg/mL or higher, transvaginal ultrasonography was performed. After confirming follicular development, ovarian stimulation was initiated using FSH agents and TI, AIH, and IVF were performed. When follicular development was not observed for 3 wk, norgestrel‐ethinylestradiol agent (PLANOVAR^®) was administered for 10‐14 d to induce withdrawal bleeding. AIH, artificial insemination of husband's semen; E, estrogen agent; E₂, estradiol; EP, norgestrel‐ethinylestradiol agent; FSH, follicle‐stimulating hormone; IVF, in vitro fertilization; LH, luteinizing hormone; P₄, progesterone; TI, timed intercourse